The Role of Bridging Therapeutic Strategies for Patients With Multiple Myeloma Receiving CAR T-Cell Therapy

Thomas G. Martin, MD, provides expert guidance on bridging and other treatment strategies for the real-world implementation of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma, including up-to-date clinical trial data and future directions affecting the placement of CAR T-cell therapy in the treatment landscape.

Share

Program Content

Activities

CAR T Bridging for MM: Module
The Role of Bridging Therapeutic Strategies for Patients With Multiple Myeloma Receiving CAR T-Cell Therapy
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: July 17, 2023

Expires: July 16, 2024

Activities

CAR T Bridging for MM: Slideset
The Role of Bridging Therapeutic Strategies for Patients With Multiple Myeloma Receiving CAR T-Cell Therapy
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 17, 2023

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb